⚖️Correction on 2-Methyl AP-237 Placement in Schedule I by DEA
On March 15, 2024, the Drug Enforcement Administration published a final order placing 1-(2-methyl-4-(3-phenylprop-2-en-1- yl)piperazin-1-yl)butan-1-one (commonly known as 2-methyl AP-237), including its optical and geometric isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation, in schedule I of the Controlled Substances Act. The effective date of that final order was 30 days after publication in the Federal Register. Before the effective date, DEA published another final order that made the instructions for 2-methyl AP-237 in the March 15 final order invalid. This document corrects that error, adding 2- methyl AP-237 and its drug code 9664 for regulatory purposes.
Learn More💊Proposed DEA Registration Information Collection Overview
The Department of Justice (DOJ), Drug Enforcement Administration (DEA), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.
Learn More💊Notice on ANI Pharmaceuticals’ Controlled Substances Import Application
ANI Pharmaceuticals Inc has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Learn More⚖️DEA Revocation of Khursheed Haider's Registration
The Drug Enforcement Administration (DEA) revoked the registration of Khursheed Haider, M.D. due to his lack of authority to practice medicine in California and handle controlled substances. As a result, business owners in the healthcare sector must remain vigilant about practitioner licensing to avoid regulatory issues.
Learn More💊Quagen Pharmaceuticals LLC's Application for Controlled Substance Import
Quagen Pharmaceuticals LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
Learn More💊Wedgewood Pharmacy Seeks Import Registration for Controlled Substances
Wedgewood Pharmacy LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Learn More⚖️DEA Revokes Registration for Dr. Edmund Ayoub Jr. Due to Compliance Issues
The Drug Enforcement Administration has revoked the registration of Dr. Edmund Ayoub Jr. due to his cessation of authority to practice medicine in California, a prerequisite for handling controlled substances. The ruling highlights the implications of regulatory compliance for medical practitioners and their business operations in the healthcare sector.
Learn More⚖️Revocation of DEA Registration for Mohan Kaza Due to Violations
The Drug Enforcement Administration issued a decision revoking Dr. Mohan Kaza's DEA registration, citing multiple violations of the Controlled Substances Act related to improper prescribing practices. The order reveals serious concerns regarding public safety and compliance with legal standards, ultimately leading to the termination of his ability to prescribe controlled substances.
Learn More⚖️DEA Registration Revocation for Prescription Violations
The Drug Enforcement Administration (DEA) issued a decision revoking a medical doctor's registration due to issuing controlled substance prescriptions without state authority, violating both federal and state law. The order underscores the importance of compliance with healthcare regulations to safeguard public health and safety.
Learn More⚖️DEA Revokes Registration for Improper Controlled Substance Prescribing
The Drug Enforcement Administration (DEA) issued a revocation order for Margaret Dennis, D.M.D., for improper prescribing of controlled substances, citing numerous violations of federal and state laws. The findings include lack of medical justification, inadequate record-keeping, and failure to monitor potential abuse, highlighting significant compliance issues within the healthcare sector.
Learn More